Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
FS Hodi, S Lee, DF McDermott, UN Rao, LH Butterfield… - Jama, 2014 - jamanetwork.com
Importance Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) blockade with
ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and
granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccine
combinations demonstrate therapeutic synergy in preclinical models. A key unanswered
question is whether systemic GM-CSF (sargramostim) enhances CTLA-4 blockade.
Objective To compare the effect of ipilimumab plus sargramostim vs ipilimumab alone on …
ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and
granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccine
combinations demonstrate therapeutic synergy in preclinical models. A key unanswered
question is whether systemic GM-CSF (sargramostim) enhances CTLA-4 blockade.
Objective To compare the effect of ipilimumab plus sargramostim vs ipilimumab alone on …